MedTrace Logo

Bone Marrow Suppression and Recovery During Radionuclide Treatment

NCT03247010 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2022-11-09

No results posted yet for this study

Summary

Radium-223-dichloride is approved therapy for patients with metastatic castration-resistant prostate cancer and bone metastases. More than 20 % of patients treated at Rigshospitalet develop bone marrow suppression as a side effect to Radium therapy The aim of the study is to examine biomarkers of bone marrow suppression and recovery during Radium therapy as well as markers of bone remodeling.

Conditions

  • Castration-resistant Prostate Cancer

Interventions

OTHER

Blood sampling

Blood samples are taken before each cycle of Radium 223

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Jann Ø Mortensen, DMSc · Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine & PET

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-20
Primary Completion
2019-10-01
Completion
2020-10-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03247010 on ClinicalTrials.gov